AI in Unexpected Places: Transforming Healthcare, Gaming, Retail, and Beyond
02 August 2024
Read Time 10+ MIN
Unexpected Industries Using AI: Healthcare, Gaming, & More
Artificial intelligence (AI) has made its mark in many unexpected places, creating innovative solutions and transforming industries in ways that were once thought impossible. From healthcare to gaming and retail, AI is driving efficiencies, enhancing user experiences, and creating new opportunities for growth. In this blog, we will explore AI’s transformative power in three unexpected industries:
- AI in Healthcare: Revolutionizing patient care and drug development.
- AI in Gaming: Enhancing player experience and game development.
- AI in Retail: Improving customer experience and operational efficiencies.
Generative AI in Healthcare
The integration of Generative AI in healthcare represents a significant leap forward in streamlining operations, reducing costs, and enhancing patient care. This advanced application of AI can transform how healthcare professionals approach their daily tasks and interact with patients.
Automating Routine Tasks
Generative AI is adept at automating routine administrative and clinical tasks, which typically consume a substantial amount of healthcare professionals' time. By handling these tasks, AI allows healthcare staff to dedicate more time to direct patient care. For instance, AI systems can automatically update patient records, schedule appointments, and manage billing, which reduces administrative burdens and minimizes the risk of human error.
Creating Personalized Treatment Plans
One of the most impactful applications of Generative AI is in the development of personalized treatment plans. By analyzing vast amounts of data from electronic health records (EHRs), genetic information, and ongoing research, AI can identify the most effective treatment options tailored to individual patient needs. This approach is particularly beneficial in complex cases such as cancer or chronic diseases, where treatment customization can significantly improve outcomes.
Predicting Patient Outcomes
Generative AI also plays a crucial role in predicting patient outcomes. It can process and analyze historical health data and current clinical inputs to forecast the progression of a disease or the likely response to a specific treatment. This capability is invaluable for proactive management of conditions, enabling interventions that are timely and more likely to succeed, thereby enhancing the quality of care and patient satisfaction.
Assisting with Diagnosis
AI's ability to assist with diagnosis is another area where it provides substantial benefits. Generative AI models are trained on vast datasets and can recognize patterns that may be subtle or complex for human eyes. For instance, AI-driven diagnostic tools can analyze imaging scans to detect abnormalities, such as tumors in their early stages, with high accuracy. This aids in early diagnosis, which is often critical for successful treatment outcomes.
Cost Reduction
By automating routine tasks, personalizing treatment plans, and improving diagnostic accuracy, Generative AI significantly cuts healthcare costs. It reduces the need for repetitive tests, unnecessary procedures, and helps in allocating resources more effectively. Hospitals and healthcare systems that adopt these AI technologies can expect not only improved patient care but also enhanced operational efficiencies, leading to substantial cost savings.
Generative AI can revolutionize the healthcare industry by providing tools that improve efficiency, reduce costs, and enhance the quality of patient care. As this technology continues to evolve and integrate deeper into various healthcare processes, its potential to transform the landscape of healthcare is immense. By embracing Generative AI, healthcare providers could ensure better health outcomes, optimized operations, and a more sustainable healthcare system.
AI in Pharmaceuticals
Pharmaceutical firms are incorporating AI in their operations to drive better patient outcomes, analyze data, and streamline drug development processes. AI is currently being implemented within the industry to reduce human error, streamline processes and analyze data to develop new pharmaceuticals. As a result, AI has the potential to improve patient outcomes, lower costs for industry participants, and revolutionize the pharmaceutical industry.
Industry-leading pharmaceutical firms are adopting artificial intelligence to drive value for the future of their enterprise. For example, companies like Eli Lilly* are leveraging AI to innovate and reduce the costs associated with drug development. Technological advancements in AI are crucial for advancing drug development and enhancing patient care, enabling faster and more accurate discovery of new therapies.
AI in Biotech
AI is revolutionizing biotech research and development by providing powerful tools for data analysis and generating valuable insights. Here’s a closer look at how specific companies are leveraging AI in this sector:
Amgen*
Amgen is at the forefront of utilizing AI to accelerate drug discovery and development. By employing AI algorithms, Amgen can analyze vast datasets of genetic information, patient records, and biological data to identify potential drug targets more quickly and accurately. AI helps streamline the process of identifying compounds that have the highest likelihood of success, significantly reducing the time and cost associated with traditional drug discovery methods. Moreover, AI-driven predictive modeling allows Amgen to simulate the effects of drugs on biological systems, enabling the design of more effective and targeted therapies.
AI's Broader Impact on Biotech
Beyond individual companies, AI is transforming the biotech landscape by enabling the development of personalized medicine and precision therapies. AI algorithms analyze patient-specific data to tailor treatments that match the genetic and biological profiles of individuals, leading to more effective and targeted interventions. This personalized approach is particularly valuable in treating complex diseases such as cancer, where AI can identify the most promising treatment options based on a patient’s unique characteristics.
Additionally, AI is facilitating the integration of multi-omics data (such as genomics, proteomics, and metabolomics) to provide a holistic understanding of biological processes. This comprehensive analysis helps researchers uncover new biomarkers, understand disease mechanisms, and develop novel therapeutic strategies. AI’s ability to synthesize and interpret vast amounts of biological data can drive innovation in biotech research and pave the way for groundbreaking discoveries.
AI in Gaming
The gaming industry has long been a testing ground for AI technologies, with AI enhancing both game development and player experience. AI can be used to create more realistic and dynamic game environments, adapt game difficulty levels, and personalize gaming experiences based on player behavior. Advanced Micro Devices (AMD)* is a key player in developing AI-powered semiconductors that improve graphics and performance in gaming consoles. Electronic Arts (EA)* uses AI to transform real-life football players into lifelike video game characters, offering players an immersive experience. AI's growing influence on game development is shaping industry trends and pushing the boundaries of what's possible in gaming.
Enhancing Game Development
AI can play a crucial role in modern game development, providing developers with tools that create more realistic and dynamic environments. These tools can generate complex game landscapes and realistic non-player character (NPC) behaviors, reducing the workload on human developers and allowing for more creative freedom in game design. AI algorithms can automate the creation of detailed textures and intricate environments, which traditionally would take countless man-hours to craft manually.
Adapting Game Difficulty Levels
AI can enhance player engagement by dynamically adjusting game difficulty. By analyzing player performance and behavior, AI can modify game challenges in real-time, providing a tailored experience that keeps the game accessible and challenging for players of all skill levels. This adaptive difficulty helps maintain a consistent level of challenge, improving player satisfaction and retention.
Personalizing Player Experience
AI-driven systems are used to personalize the gaming experience, making it more engaging for each player. By observing a player’s choices and behaviors, AI can alter game narratives and interactions to fit individual preferences. This customization extends to recommending game content that aligns with the player's interests, further enhancing their engagement with the game.
Electronic Arts (EA)
Electronic Arts utilizes AI to bring a high level of realism and interactivity to its games. A notable application is in sports games like FIFA, where EA uses AI to transform real-life football players into detailed, lifelike video game characters. This is achieved through sophisticated motion capture technologies combined with AI algorithms that analyze and replicate player movements, facial expressions, and even playing styles. By incorporating these realistic simulations, EA provides gamers with an immersive experience that closely mirrors actual sporting events.
EA also leverages AI in enhancing gameplay mechanics and interactivity. For instance, AI is used to improve NPC intelligence, making them react more realistically to player actions and decisions within the game. This leads to more believable and responsive game worlds where each player’s actions have a profound impact on the game environment and narrative.
Shaping Industry Trends
The influence of AI progresses in the broader gaming industry trends. Developers are increasingly adopting AI to push the boundaries of what games can offer, from deeply immersive virtual realities to complex, evolving storylines that adapt to player decisions. AI is also instrumental in the development of augmented reality (AR) and virtual reality (VR), where it helps to create more immersive and interactive experiences.
AI in Retail
AI is transforming the retail industry by offering solutions that enhance customer experience, optimize inventory management, and streamline supply chain operations. Here’s a detailed look at how AI is driving these changes and the impact on major players like Amazon* and JD.com*:
Enhancing Customer Experience
AI technologies are central to creating personalized and engaging shopping experiences for customers. By analyzing vast amounts of customer data, AI can identify patterns and preferences, enabling retailers to tailor marketing efforts to individual shoppers. This personalization is evident in targeted advertisements, customized email campaigns, and product recommendations that align with a customer's past behavior and interests.
AI-powered chatbots and virtual assistants are also improving customer service by providing instant support and answers to queries, enhancing the overall shopping experience. These AI-driven tools can handle a wide range of customer interactions, from answering frequently asked questions to assisting with product selection and purchase decisions.
Optimizing Inventory Management
Effective inventory management is crucial for retailers to meet customer demands without overstocking. AI plays a significant role in predicting demand trends by analyzing historical sales data, market conditions, and external factors such as seasonality and promotions. These insights allow retailers to make informed decisions about stock levels, minimizing excess inventory and reducing holding costs.
AI systems can also enable real-time inventory tracking, ensuring that stock levels are accurately monitored across various locations. This capability helps retailers quickly identify and address discrepancies, leading to more efficient inventory management and reduced waste.
Streamlining Supply Chain Operations
AI is revolutionizing supply chain management by automating and optimizing various processes, resulting in faster and more efficient operations. Machine learning algorithms analyze data from multiple sources to identify bottlenecks, optimize delivery routes, and predict potential disruptions. This proactive approach allows retailers to mitigate risks and maintain smooth operations.
AI-driven robotics and automation systems are increasingly used in warehouses to improve picking, packing, and sorting processes. These technologies increase efficiency and accuracy while reducing labor costs and the likelihood of human error.
Amazon: Leading the Way in AI Integration
Amazon is a pioneer in using AI to transform its retail operations. The company employs AI to manage its vast inventory and automate its supply chain, ensuring products are delivered to customers quickly and efficiently. Amazon’s AI systems analyze customer purchasing patterns and trends to optimize inventory placement, reducing delivery times and costs.
The company’s AI-driven recommendation engine is a prime example of how AI enhances customer experience. By analyzing customer behavior, the recommendation engine suggests products that are most likely to interest individual shoppers, driving sales and customer satisfaction.
How Semiconductors are Fueling the AI Industry
The development of advanced semiconductors is crucial to the growth of artificial intelligence, as they provide the necessary processing power to run complex AI algorithms efficiently. Semiconductors, particularly those designed for AI applications, enable the rapid processing of vast amounts of data, making them indispensable in powering AI technologies across various industries.
Key Roles of Semiconductors in AI
- Processing Power: Semiconductors are the backbone of AI computing, providing the raw processing power required to handle intensive computations. This is particularly important for AI tasks such as machine learning and deep learning, which involve large-scale data processing and complex mathematical operations.
- Energy Efficiency: Advanced semiconductors are designed to deliver high performance while minimizing energy consumption. This efficiency is vital for AI applications that require constant processing, such as real-time data analysis and autonomous systems, where energy constraints can be a significant concern.
- Scalability: Semiconductor technology enables the scaling of AI systems to accommodate growing data volumes and increasing computational demands. With advancements in semiconductor design, such as smaller transistor sizes and innovative architectures, AI systems can be scaled to meet the needs of diverse applications, from cloud computing to edge devices.
- Specialized AI Chips: The development of specialized AI chips, such as Graphics Processing Units (GPUs), Tensor Processing Units (TPUs), and Application-Specific Integrated Circuits (ASICs), has been instrumental in accelerating AI performance. These chips are optimized for parallel processing and efficient execution of AI algorithms, offering significant advantages over traditional Central Processing Units (CPUs).
Impact on AI-Driven Industries
The continued development of advanced semiconductors is vital to the progress of AI, providing the foundation for innovations that drive the industry forward. As semiconductor technologies evolve, they could unlock new possibilities for AI applications across diverse sectors, enhancing capabilities and expanding the reach of AI solutions. For a comprehensive analysis of how semiconductors are shaping the AI landscape, you can explore VanEck's 2023 Semiconductor Outlook.
Conclusion
AI is reshaping industries across the board, from healthcare and pharmaceuticals to gaming and retail. As AI continues to evolve, its applications will expand, driving innovation and efficiency in even more unexpected areas.
To learn more about ways to invest in AI and related sectors, please explore the VanEck strategies below:
Ticker | Name |
CURE | Genomics and Healthcare Innovators UCITS ETF |
ESPO | Video Gaming and eSports UCITS ETF |
CYBO | Bionic Engineering UCITS ETF |
SMH | Semiconductor UCITS ETF |
To receive more Insights, sign up to our newsletter.
Liquidity risk: Exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all.
Equity Market Risk: The prices of the securities in the Fund are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in the Fund may lose money.
Industry or Sector Concentration Risk: The Fund’s assets may be concentrated in one or more particular sectors or industries. The Fund may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund’s assets were invested in a wider variety of sectors or industries.
Risk of investing in smaller companies: The securities of smaller companies may be more volatile and less liquid than the securities of large companies. Smaller companies, when compared with larger companies, may have a shorter history of operations, fewer financial resources, less competitive strength, may have a less diversified product line, may be more susceptible to market pressure and may have a smaller market for their securities.
IMPORTANT INFORMATION
This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.
This information originates from VanEck Switzerland AG which has been appointed as distributor of VanEck products in Switzerland by the Management Company VanEck Asset Management B.V., incorporated under Dutch law and registered with the Dutch Authority for the Financial Markets (AFM). VanEck Switzerland AG’s registered address is at Genferstrasse 21, 8002 Zürich, Switzerland.
The information is intended only to provide general and preliminary information to investors and shall not be construed as investment, legal or tax advice. VanEck Switzerland AG and its associated and affiliated companies (together “VanEck”) assume no liability with regards to any investment, divestment or retention decision taken by the investor on the basis of this information. The views and opinions expressed are those of the author(s) but not necessarily those of VanEck. Opinions are current as of the publication date and are subject to change with market conditions. Certain statements contained herein may constitute projections, forecasts and other forward-looking statements, which do not reflect actual results. Information provided by third party sources is believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. Brokerage or transaction fees may apply. A copy of the latest prospectus, the Articles, the Key Information Document, the annual report and semi-annual report can be found on our website www.vaneck.com or can be obtained free of charge from the representative in Switzerland: First Independent Fund Services Ltd, Feldeggstrasse 12, 8008 Zurich, Switzerland.
Swiss paying agent: Helvetische Bank AG, Seefeldstrasse 215, CH-8008 Zürich.
VanEck Asset Management B.V., the management company of VanEck Genomics and Healthcare Innovators UCITS ETF (the "ETF"), a sub-fund of VanEck UCITS ETFs plc, is a UCITS management company incorporated under Dutch law registered with the Dutch Authority for the Financial Markets (AFM). The ETF is registered with the Central Bank of Ireland, passively managed and tracks an equity index. The value of the ETF assets may fluctuate heavily as a result of the investment strategy. Investing in the ETF should be interpreted as acquiring shares of the ETF and not the underlying assets.
VanEck Asset Management B.V., the management company of VanEck Video Gaming and eSports UCITS ETF (the "ETF"), a sub-fund of VanEck UCITS ETFs plc, is a UCITS management company incorporated under Dutch law and registered with the Dutch Authority for the Financial Markets (AFM). The ETF is registered with the Central Bank of Ireland, passively managed and tracks an equity index. Investing in the ETF should be interpreted as acquiring shares of the ETF and not the underlying assets.
VanEck Asset Management B.V., the management company of VanEck Bionic Engineering UCITS ETF (the "ETF"), a sub-fund of VanEck UCITS ETFs plc, is a UCITS management company incorporated under Dutch law registered with the Dutch Authority for the Financial Markets (AFM). The ETF is registered with the Central Bank of Ireland, passively managed and tracks an equity index. Investing in the ETF should be interpreted as acquiring shares of the ETF and not the underlying assets.
VanEck Asset Management B.V., the management company of VanEck Semiconductor UCITS ETF (the "ETF"), a sub-fund of VanEck UCITS ETFs plc, is a UCITS management company incorporated under Dutch law registered with the Dutch Authority for the Financial Markets (AFM). The ETF is registered with the Central Bank of Ireland, passively managed and tracks an equity index. Investing in the ETF should be interpreted as acquiring shares of the ETF and not the underlying assets.
All performance information is based on historical data and does not predict future returns. Investing is subject to risk, including the possible loss of principal.
No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.
© VanEck Switzerland AG
Important Disclosure
This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.
This information originates from VanEck Switzerland AG which has been appointed as distributor of VanEck products in Switzerland by the Management Company VanEck Asset Management B.V., incorporated under Dutch law and registered with the Dutch Authority for the Financial Markets (AFM). VanEck Switzerland AG’s registered address is at Genferstrasse 21, 8002 Zürich, Switzerland.
The information is intended only to provide general and preliminary information to investors and shall not be construed as investment, legal or tax advice. VanEck Switzerland AG and its associated and affiliated companies (together “VanEck”) assume no liability with regards to any investment, divestment or retention decision taken by the investor on the basis of this information. The views and opinions expressed are those of the author(s) but not necessarily those of VanEck. Opinions are current as of the publication date and are subject to change with market conditions. Certain statements contained herein may constitute projections, forecasts and other forward-looking statements, which do not reflect actual results. Information provided by third party sources is believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. Brokerage or transaction fees may apply. A copy of the latest prospectus, the Articles, the Key Information Document, the annual report and semi-annual report can be found on our website www.vaneck.com or can be obtained free of charge from the representative in Switzerland: First Independent Fund Services Ltd, Feldeggstrasse 12, 8008 Zurich, Switzerland. Swiss paying agent: Helvetische Bank AG, Seefeldstrasse 215, CH-8008 Zürich.
All performance information is based on historical data and does not predict future returns. Investing is subject to risk, including the possible loss of principal.
No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.
© VanEck Switzerland AG
Sign-up for our ETF newsletter
Related Insights
Related Insights
20 November 2024
14 November 2024